Counting the Cost of a Molecule That Never Went on Sale

When the Food and Drug Administration declined an NGF-inhibitor program for chronic pain, most coverage focused on safety signals and patient populations. Far less attention went to a quieter question: what does a drug like this actually cost — not to make, but to value? For compounds that never reach the market, pricing is not an afterthought. It is a discipline that begins a decade before a launch that may never happen.

Pricing Begins in the Business Plan, Not the Pharmacy

Large pharmaceutical companies build internal revenue models for investigational drugs at the phase II stage, sometimes earlier. Analysts project peak-year sales, market share, and a plausible launch price range based on the therapeutic class the drug would compete in — regardless of whether the trial program succeeds.

For a monoclonal antibody targeting chronic musculoskeletal pain, those models would have looked at an obvious benchmark: the existing injectable pain and osteoarthritis landscape in the United States. Injectable biologics for osteoarthritis, such as corticosteroid and hyaluronic acid preparations, carry list prices that commonly range from several hundred to a few thousand dollars per treatment course. A novel biologic with a mechanism of action not yet on the market would almost certainly have been positioned at the upper end of that spectrum, with internal modeling likely contemplating a per-dose figure in the low-to-mid four figures.

None of this requires approval. It requires only a credible path to one.

Why Companies Price Drugs That May Never Sell

Three practical reasons drive this behavior.

First, licensing. A compound with strong phase II data carries negotiating value in partnership deals, and those negotiations demand a defensible revenue forecast. A price assumption is embedded in every term sheet.

Second, trial economics. Payer engagement — the conversations manufacturers hold with insurers about coverage evidence — starts during phase III. Insurers ask, quite reasonably, what the drug will cost. A manufacturer that cannot answer credibly cannot secure the coverage commitments that make a launch viable.

Third, investor communication. Public companies guide markets on pipeline value. Every earnings call that mentions a phase III pain asset implicitly prices it.

In other words, a rejected drug like tanezumab was priced, modeled, and valued for years — by its developer, by its partners, and by the analysts who covered them — without ever appearing on a single formulary.

What the Counterfactual Price Would Likely Have Been

Any estimate of what tanezumab would have cost is necessarily speculative, but the architecture of the estimate is not. Biologic pricing in the U.S. follows recognizable patterns:

• Mechanism novelty commands a premium. First-in-class agents historically launch above the prevailing class average.
• Chronic-use drugs are priced per dose with frequency in mind. A quarterly or every-eight-week injection supports a higher per-dose price than a daily oral.
• Specialty distribution adds layers. A drug requiring clinical administration carries buy-and-bill dynamics that inflate the realized price well beyond the manufacturer's list figure.

Combining these factors, a plausible modeled launch price would have sat comfortably within the range occupied by other specialty injectables for chronic conditions — likely several thousand dollars per dose before rebates, with net prices after payer negotiation substantially lower. The gap between list and net is where much of the real economics lives, and it is precisely the gap that current transparency debates in Washington are trying to illuminate.

The Afterlife of a Priced-but-Unlaunched Drug

A regulatory rejection does not zero out a compound's book value. As previous coverage on this site has noted, shelved molecules are licensed, repurposed, and traded. Their internal price models are revised, not discarded — recalibrated for new indications, new markets, or new development partners.

For researchers and policy analysts, this matters. Pricing assumptions made for a drug that never launched still shape how developers value the next pain asset in the pipeline. If a company spent more than a decade and an estimated several hundred million dollars on a program that ended at a complete response letter, that sunk cost becomes a data point in the next negotiation — and, indirectly, in the next launch price.

Why Patients Should Care

The relevance for people living with chronic pain is not academic. When a non-opioid analgesic fails at the regulatory stage, the pipeline narrows, and the pricing of whatever succeeds later reflects both the unmet need and the failed predecessor's economics. Understanding that pricing is drafted years before approval — and that rejection does not erase it — gives patients, clinicians, and advocates a clearer picture of why the non-opioid pipeline looks the way it does.

The price of a pinched nerve, it turns out, was calculated long before anyone had the chance to pay it.